Aptamer internalization via endocytosis inducing s-phase arrest and priming maver-1 lymphoma cells for cytarabine chemotherapy

Huan Li, Shuanghui Yang, Ge Yu, Liangfang Shen, Jia Fan, Ling Xu, Hedong Zhang, Nianxi Zhao, Zihua Zeng, Ye Hu, Jianguo Wen, Youli Zu

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The goal of precision therapy is to efficiently treat cancer without side effects. Aptamers are a class of small ligands composed of single-stranded oligonucleotides that bind to their targets with high affinity and specificity. In this study, we identified an ssDNA aptamer specifically targeting Maver-1 lymphoma cells with high binding affinity (Kd = 70±8 pmol/L). Interestingly, cellular cycle studies revealed that exposure of Maver-1 cells to synthetic aptamers triggered S-phase arrest of 40% of the cells (vs. 18% baseline). Confocal microscopy confirmed specific cell binding of aptamers and the resultant endocytosis into Maver-1 cells. Subsequent functional assays validated the fact that aptamer internalization into targeted cells is a prerequisite for Maver-1 cell growth inhibition. Importantly, aptamer-induced S-phase arrest induced enhanced chemotherapeutic results involving cytarabine, which primarily kills lymphoma cells at S-phase. Combination treatments revealed that aptamer re-exposure considerably primed Maver-1 cells for cytarabine chemotherapy, thus achieving a synergistic killing effect by reaching cell death rates as high as 61% (vs. 13% or 14% induced by aptamer or cytarabine treatment alone). These findings demonstrated that aptamers do not only act as molecular ligands but can also function as biotherapeutic agents by inducing S-phase arrest of lymphoma cells. In addition, logical combination of aptamer and cytarabine treatments ushers the way to a unique approach in precision lymphoma chemotherapy.

Original languageEnglish (US)
Pages (from-to)1204-1213
Number of pages10
JournalTheranostics
Volume7
Issue number5
DOIs
StatePublished - Jan 1 2017
Externally publishedYes

Fingerprint

Cytarabine
Endocytosis
Lymphoma
Drug Therapy
S Phase
Ligands
Artificial Cells
Therapeutics
Confocal Microscopy
Oligonucleotides
Cell Death
Mortality
Growth

Keywords

  • Aptamer
  • Biotherapeutics
  • Lymphoma
  • S-phase arrest
  • Synergistic chemotherapy

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Pharmacology, Toxicology and Pharmaceutics (miscellaneous)

Cite this

Aptamer internalization via endocytosis inducing s-phase arrest and priming maver-1 lymphoma cells for cytarabine chemotherapy. / Li, Huan; Yang, Shuanghui; Yu, Ge; Shen, Liangfang; Fan, Jia; Xu, Ling; Zhang, Hedong; Zhao, Nianxi; Zeng, Zihua; Hu, Ye; Wen, Jianguo; Zu, Youli.

In: Theranostics, Vol. 7, No. 5, 01.01.2017, p. 1204-1213.

Research output: Contribution to journalArticle

Li, Huan ; Yang, Shuanghui ; Yu, Ge ; Shen, Liangfang ; Fan, Jia ; Xu, Ling ; Zhang, Hedong ; Zhao, Nianxi ; Zeng, Zihua ; Hu, Ye ; Wen, Jianguo ; Zu, Youli. / Aptamer internalization via endocytosis inducing s-phase arrest and priming maver-1 lymphoma cells for cytarabine chemotherapy. In: Theranostics. 2017 ; Vol. 7, No. 5. pp. 1204-1213.
@article{b71efab32f47473b9bb20cf39f22d2c4,
title = "Aptamer internalization via endocytosis inducing s-phase arrest and priming maver-1 lymphoma cells for cytarabine chemotherapy",
abstract = "The goal of precision therapy is to efficiently treat cancer without side effects. Aptamers are a class of small ligands composed of single-stranded oligonucleotides that bind to their targets with high affinity and specificity. In this study, we identified an ssDNA aptamer specifically targeting Maver-1 lymphoma cells with high binding affinity (Kd = 70±8 pmol/L). Interestingly, cellular cycle studies revealed that exposure of Maver-1 cells to synthetic aptamers triggered S-phase arrest of 40{\%} of the cells (vs. 18{\%} baseline). Confocal microscopy confirmed specific cell binding of aptamers and the resultant endocytosis into Maver-1 cells. Subsequent functional assays validated the fact that aptamer internalization into targeted cells is a prerequisite for Maver-1 cell growth inhibition. Importantly, aptamer-induced S-phase arrest induced enhanced chemotherapeutic results involving cytarabine, which primarily kills lymphoma cells at S-phase. Combination treatments revealed that aptamer re-exposure considerably primed Maver-1 cells for cytarabine chemotherapy, thus achieving a synergistic killing effect by reaching cell death rates as high as 61{\%} (vs. 13{\%} or 14{\%} induced by aptamer or cytarabine treatment alone). These findings demonstrated that aptamers do not only act as molecular ligands but can also function as biotherapeutic agents by inducing S-phase arrest of lymphoma cells. In addition, logical combination of aptamer and cytarabine treatments ushers the way to a unique approach in precision lymphoma chemotherapy.",
keywords = "Aptamer, Biotherapeutics, Lymphoma, S-phase arrest, Synergistic chemotherapy",
author = "Huan Li and Shuanghui Yang and Ge Yu and Liangfang Shen and Jia Fan and Ling Xu and Hedong Zhang and Nianxi Zhao and Zihua Zeng and Ye Hu and Jianguo Wen and Youli Zu",
year = "2017",
month = "1",
day = "1",
doi = "10.7150/thno.17069",
language = "English (US)",
volume = "7",
pages = "1204--1213",
journal = "Theranostics",
issn = "1838-7640",
publisher = "Ivyspring International Publisher",
number = "5",

}

TY - JOUR

T1 - Aptamer internalization via endocytosis inducing s-phase arrest and priming maver-1 lymphoma cells for cytarabine chemotherapy

AU - Li, Huan

AU - Yang, Shuanghui

AU - Yu, Ge

AU - Shen, Liangfang

AU - Fan, Jia

AU - Xu, Ling

AU - Zhang, Hedong

AU - Zhao, Nianxi

AU - Zeng, Zihua

AU - Hu, Ye

AU - Wen, Jianguo

AU - Zu, Youli

PY - 2017/1/1

Y1 - 2017/1/1

N2 - The goal of precision therapy is to efficiently treat cancer without side effects. Aptamers are a class of small ligands composed of single-stranded oligonucleotides that bind to their targets with high affinity and specificity. In this study, we identified an ssDNA aptamer specifically targeting Maver-1 lymphoma cells with high binding affinity (Kd = 70±8 pmol/L). Interestingly, cellular cycle studies revealed that exposure of Maver-1 cells to synthetic aptamers triggered S-phase arrest of 40% of the cells (vs. 18% baseline). Confocal microscopy confirmed specific cell binding of aptamers and the resultant endocytosis into Maver-1 cells. Subsequent functional assays validated the fact that aptamer internalization into targeted cells is a prerequisite for Maver-1 cell growth inhibition. Importantly, aptamer-induced S-phase arrest induced enhanced chemotherapeutic results involving cytarabine, which primarily kills lymphoma cells at S-phase. Combination treatments revealed that aptamer re-exposure considerably primed Maver-1 cells for cytarabine chemotherapy, thus achieving a synergistic killing effect by reaching cell death rates as high as 61% (vs. 13% or 14% induced by aptamer or cytarabine treatment alone). These findings demonstrated that aptamers do not only act as molecular ligands but can also function as biotherapeutic agents by inducing S-phase arrest of lymphoma cells. In addition, logical combination of aptamer and cytarabine treatments ushers the way to a unique approach in precision lymphoma chemotherapy.

AB - The goal of precision therapy is to efficiently treat cancer without side effects. Aptamers are a class of small ligands composed of single-stranded oligonucleotides that bind to their targets with high affinity and specificity. In this study, we identified an ssDNA aptamer specifically targeting Maver-1 lymphoma cells with high binding affinity (Kd = 70±8 pmol/L). Interestingly, cellular cycle studies revealed that exposure of Maver-1 cells to synthetic aptamers triggered S-phase arrest of 40% of the cells (vs. 18% baseline). Confocal microscopy confirmed specific cell binding of aptamers and the resultant endocytosis into Maver-1 cells. Subsequent functional assays validated the fact that aptamer internalization into targeted cells is a prerequisite for Maver-1 cell growth inhibition. Importantly, aptamer-induced S-phase arrest induced enhanced chemotherapeutic results involving cytarabine, which primarily kills lymphoma cells at S-phase. Combination treatments revealed that aptamer re-exposure considerably primed Maver-1 cells for cytarabine chemotherapy, thus achieving a synergistic killing effect by reaching cell death rates as high as 61% (vs. 13% or 14% induced by aptamer or cytarabine treatment alone). These findings demonstrated that aptamers do not only act as molecular ligands but can also function as biotherapeutic agents by inducing S-phase arrest of lymphoma cells. In addition, logical combination of aptamer and cytarabine treatments ushers the way to a unique approach in precision lymphoma chemotherapy.

KW - Aptamer

KW - Biotherapeutics

KW - Lymphoma

KW - S-phase arrest

KW - Synergistic chemotherapy

UR - http://www.scopus.com/inward/record.url?scp=85014665602&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014665602&partnerID=8YFLogxK

U2 - 10.7150/thno.17069

DO - 10.7150/thno.17069

M3 - Article

VL - 7

SP - 1204

EP - 1213

JO - Theranostics

JF - Theranostics

SN - 1838-7640

IS - 5

ER -